Announced Mon, 16 Mar · 12:02 IST

The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sudhir Sethi

Promoter Stake BuyCreeping Acquisition Near ThresholdOwnership Changes View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-4.7%1-day move

₹20.20

prior close

₹20.70

base price

In-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+0.0+0.0+0.0+0.0-4.7-1.0+3.9+5.9+1.5+0.5+28.7+21.4-0.5+16.3

Up moveDown movePending

AI summary

Promoter Mr. Sudhir Sethi bought 3,040 equity shares (0.06%) of Beryl Drugs Limited through open market transactions on March 13, 2026. His stake in the company rose from 9.27% (4,70,143 shares) to 9.33% (4,73,183 shares) of the total equity share capital of 50,71,700 shares. The disclosure was filed under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The acquisition is incremental and was carried out in his personal capacity as a promoter of the company.

Likely market impact

The purchase is too small to materially affect the stock price, but signals continued promoter confidence in the company. With the promoter now at 9.33%, any further purchases will cross the 10% threshold, triggering additional disclosure requirements under SAST rules.